SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-22-284558 from Annexon, Inc. (ANNX) (CIK 0001528115) (ANNX)

Annexon, Inc. (ANNX) (CIK 0001528115)
Date: Nov. 14, 2022 · CIK: 0001528115 · Accession: 0001193125-22-284558

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-268181

Date
November 4, 2022
Author
By
Form
CORRESP
Company
Annexon, Inc. (ANNX) (CIK 0001528115)

Letter

Annexon, Inc.

1400 Sierra Point Parkway, Bldg C, Suite 200

Brisbane, California 94005

November 14,

Via EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Re: Annexon, Inc.

Registration Statement on Form S-3

Filed November 4, 2022

Registration No. 333-268181

To whom it may concern:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Annexon, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on November 16, 2022, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. Please contact Kathleen M. Wells of Latham & Watkins LLP, counsel to the Company, at (650) 463-2677, or in her absence, Richard Kim of Latham & Watkins LLP at (650) 470-4980, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

Thank you for your assistance in this matter.

* * * *

Sincerely,
Annexon, Inc.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 Annexon, Inc.

1400 Sierra Point Parkway, Bldg C, Suite 200

Brisbane, California 94005

 November 14,
2022

 Via EDGAR

 United States Securities and
Exchange Commission

 Division of Corporation Finance

 Office
of Life Sciences

 100 F Street, N.E.

 Washington, D.C. 20549

Re:
 Annexon, Inc.

Registration Statement on Form S-3

Filed November 4, 2022

Registration No. 333-268181

To whom it may concern:

 Pursuant to Rule
461(a) under the Securities Act of 1933, as amended, Annexon, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and
Exchange Commission to 4:00 p.m. Washington D.C. time on November 16, 2022, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. Please contact Kathleen M. Wells
of Latham & Watkins LLP, counsel to the Company, at (650) 463-2677, or in her absence, Richard Kim of Latham & Watkins LLP at (650) 470-4980, to
provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

 Thank you for your assistance in
this matter.

 *    *    *    *

Sincerely,

Annexon, Inc.

By:

 /s/ Jennifer Lew

Jennifer Lew

Chief Financial Officer and Secretary

cc:
 Douglas Love, Esq., Annexon, Inc.

Kathleen M. Wells, Latham & Watkins LLP

Brian J. Cuneo, Latham & Watkins LLP

Richard Kim, Latham & Watkins LLP